Best of the Week
Most Popular
1.UK General Election BBC Exit Polls Forecast Accuracy - Nadeem_Walayat
2.UK General Election 2017 Seats Final Forecast, Labour, Conservative Lib-Dem, SNP - Nadeem_Walayat
3.UK General Election 2017 Forecast: Conservative 358, Labour 212 Seats - Nadeem_Walayat
4.Theresa May to Resign, Fatal Error Was to Believe Worthless Opinion Polls! - Nadeem_Walayat
5.UK House Prices Forecast General Election 2017 Conservative Seats Result - Nadeem_Walayat
6.The Stock Market Crash of 2017 That Never Was But Could it Still Come to Pass? - Sol_Palha
7.[TRADE ALERT] Write This Gold Stock Ticker Down Now - WallStreetNation
8.UK General Election Results Map 2017 vs 2015 vs Opinion Polls - Nadeem_Walayat
9.Orphaned Poisoned Waters,Severe Chronic Water Shortage Imminent - Richard_Mills
10.How The Smart Money Is Playing The Lithium Boom - OilPrice_Com
Last 7 days
Grenfell Fire: 600 of 4000 Tower Blocks Ticking Time Bomb Death Traps! - 22nd Jun 17
Car Sales About To Go Over The Cliff - 22nd Jun 17
LOG 0.786 support in CRUDE OIL and COCOA - 22nd Jun 17
More Stock Market Fluctuations Along New Record Highs - 22nd Jun 17
Understanding true money, Pound Sterling must make another historic low, Euro and Gold outlook! - 22nd Jun 17
Green Party Could Control Sheffield City Council Balance of Power Local Election 2018 - 22nd Jun 17
Ratio Combo Charts : Hidden Clues to the Gold Market Puzzle - 22nd Jun 17
Steem Hard Forks & Now People Are Making Even More Money On Blockchain Steemit - 22nd Jun 17
4 Steps for Comparing Binary Options Providers - 22nd Jun 17
Nether Edge & Sharrow By-Election, Will Labour Lose Safe Council Seat, Sheffield? - 21st Jun 17
Stock Market SPX Making New Lows - 21st Jun 17
Your Future Wealth Depends on what You Decide to Keep and Invest in Now - 21st Jun 17
Either Bitcoin Will Fail OR Bitcoin Is A Government Invention Meant To Enslave... - 21st Jun 17
Strength in Gold and Silver Mining Stocks and Its Implications - 21st Jun 17
Inflation is No Longer in Stealth Mode - 21st Jun 17
CRUDE OIL UPDATE- “0.30 risk is cheap for changing implication!” - 20th Jun 17
Crude Oil Verifies Price Breakdown – Or Is It Something More? - 20th Jun 17
Trump Backs ISIS As He Pushes US Onto Brink of World War III With Russia - 20th Jun 17
Most Popular Auto Trading Tools for trading with Stock Markets - 20th Jun 17
GDXJ Gold Stocks Massacre: The Aftermath - 20th Jun 17
Why Walkers Crisps Pay Packet Promotion is RUBBISH! - 20th Jun 17
7 Signs You Should Add Gold To Your Portfolio Now - 19th Jun 17
US Bonds and Related Market Indicators - 19th Jun 17
Wireless Wars: The Billion Dollar Tech Boom No One Is Talking About - 19th Jun 17
Amey Playing Cat and Mouse Game with Sheffield Residents and Tree Campaigners - 19th Jun 17
Positive Stock Market Expectations, But Will Uptrend Continue? - 19th Jun 17
Gold Proprietary Cycle Indicator Remains Down - 19th Jun 17
Stock Market Higher Highs Still Likely - 18th Jun 17
The US Government Clamps Down on Ability of Americans To Purchase Bitcoin - 18th Jun 17
NDX/NAZ Continue downward pressure on the US Stock Market - 18th Jun 17
Return of the Gold Bear? - 18th Jun 17
Are Sheffield's High Rise Tower Blocks Safe? Grenfell Cladding Fire Disaster! - 18th Jun 17
Globalist Takeover Of The Internet Moves Into Overdrive - 17th Jun 17
Crazy Charging Stocks Bull Market Random Thoughts - 17th Jun 17
Reflation, Deflation and Gold - 17th Jun 17
Here’s The Case For An Upside Risk In The Global Economy - 17th Jun 17
Gold Bullish on Fed Interest Rate Hike - 16th Jun 17
Drones Upending Business Models and Reshaping Industry Landscapes - 16th Jun 17
Grenfell Tower Cladding Fire Disaster, 4,000 Ticking Time Bombs, Sheffield Council Flats Panic! - 16th Jun 17
Heating Oil Bottom Is In.(probably) - 16th Jun 17
Here’s the Investing Reason Active Funds Can’t Beat Passive Funds—and It Worries Me a Lot - 16th Jun 17
Is There Gold “Hype” and is Gold an Emotional Trade? - 16th Jun 17
The War On Cash Is Now Becoming The War On Cryptocurrency - 15th Jun 17
The US Dollar Bull Case - 15th Jun 17
The Pros and Cons of Bitcoin and Blockchain - 15th Jun 17
The Retail Sector Downfall We Saw Coming - 15th Jun 17
Charts That Explain Why The US Rule Oil Prices Not OPEC - 15th Jun 17
How to Find the Best Auto Loan - 15th Jun 17
Ultra-low Stock Market Volatility #ThisTimeIsDifferent - 14th Jun 17
DOLLAR has recently damaged GOLD and SILVER- viewed in MRI 3D charts - 14th Jun 17
US Dollar Acceleration Phase is Dead Ahead! - 14th Jun 17
Hit or Pass? An Overview of 2017’s Best Ranked Stocks - 14th Jun 17
Rise Gold to Recommence Work at Idaho Maryland Mine After 60 Years - 14th Jun 17
Stock Market Tech Shakeout! - 14th Jun 17
The #1 Gold Stock of 2017 - 14th Jun 17

Market Oracle FREE Newsletter

The MRI 3D Report

Biotech Breakthrough Could Create A $11.4 Trillion Opportunity

Companies / BioTech Jan 18, 2017 - 01:07 AM GMT

By: OilPrice_Com

Companies

A little-known biotech company is poised to potentially earn millions in revenue with the planned upcoming release of a breakthrough technology that could prevent massive numbers of strokes with a simple test that is affordable and accessible to the average American.


A Multi-Billion-Dollar Problem with a $49,000 Answer

Stroke statistics are shocking: Globally, every year 15 million people suffer a stroke. Of these, some 6 million are killed, while 5 million are rendered permanently disabled. In the U.S. alone, nearly 800,000 people suffer from strokes annually—and someone dies of a stroke every 4 minutes.

Until now, there has been no cost-effective way to screen for Ischemia, the leading indicator of a stroke, which cost the U.S. government alone tens of billions of dollars a year. That could be about to change, thanks to a breakthrough technology from CVR Medical (TSX:CVM.V ; OTC:CRRVF. The company’s debut, game-changing medical device has been quietly in development for 10 years, and now it’s about to charge out of the gate, hoping to take the market by storm upon FDA market clearance.  

What 3D seismic imagery did for super quick discoveries in the oil and gas industry, CVR’s  sensory system could do for the medical industry.

CVR’s Carotid Stenotic Scan (CSS) is a tool to detect stenosis within the Carotid Arteries, potentially offering patients and caregivers a device for early detection in a quick and repeatable manner. Unlike other comparative modalities, the CSS was designed to function without the assistance of a certified technician.  These three facts combine to create one of the potentially biggest—and most lucrative--phenomena in recent medical equipment market history.

The CSS makes a connection between fluid flow and sub-sonic frequencies to detect arterial disease or blockage. Blood flowing through the carotid arteries produces wave patterns which are shaped and altered by the presence of irregularities on the inner artery walls. CVR’s advanced technology captures these wave patterns and analyzes them mathematically with patented algorithms. After a brief test, the analysis is complete, offering a way to potentially identify those at risk of a stroke and arming the healthcare provider with the information necessary to prevent the deadly event. For investors, medical providers, insurers, and the public at large, the secondary benefit is that this new innovation has a price tag that renders testing up to 50 times cheaper than many tools on the market today.

Coming in at $49,000 per unit, compared to up to a whopping US$2.5 million for existing technology.

Additionally, some existing technologies are invasive and, due to cost, not accessible to many. CVR’s CSS is positioned to potentially fill this current gap. Once available, the CSS technology stands to save the U.S. government up to US$34 billion a year, the current cost of strokes annually in the U.S. according to the CDC.

With strokes coming in as the second leading cause of death globally for people over the age of 60, and the fifth leading cause of death for people aged 15-59, a new technology that can deliver early detection is beyond critical.

According to the CDC, early action is urgent for survival, and only 38 percent of stroke sufferers even recognize they are having a stroke in time to receive effective emergency intervention.

2017: The Definitive Year of Biotech

This is where the new barons are being made, with medical breakthroughs turning countless billions in new profits—and 2017 is set to be the strongest ever.  

  • Biotech companies pivoting to microbiome to develop new diagnostics, new therapies and probiotic products to prevent dangerous microbe imbalances are set to cement themselves as one of the industry’s most promising and lucrative “frontiers” this year.
  • Cellular immunotherapies reporting 90 percent remission rates for acute lymphoblastic leukemia (ALL) is expected to be presented to the FDA in 2017 and could trigger a wave of approvals for other blood cancers and lymphomas, and could eventually replace chemotherapy.
  • Liquid biopsies, or blood tests that uncover signs of actual DNA or cell-free circulating tumor DNA (ctDNA), could prove to be a revolutionary cancer test with annual sales forecast to be $10 billion.
  • Bioabsorbable stents, approved in the U.S. in July for the first time, has a market potential approaching $2 billion in six years, with this year the critical juncture.
  • CVR invested $23 million in its breakthrough technology, with early stage clinical trials complete and now headed toward pivotal trials, eyeing the potential for immediate profitability, with possible U.S. sales alone up to 400,000 devices annually at $49,000 each. When you talk globally, the numbers are staggering.

There’s nothing more gratifying than getting in on the ground floor of a medical equipment breakthrough that can save millions of lives and turn a fantastic profit while doing it.

Here are 3 reasons to keep a close eye on CVR Medical right now:

  1. Urgent Need, Guaranteed Market

Few things are more urgent that an early detection system for a medical condition that kills 6 million people a year. In the U.S. alone, one American dies from stroke every 4 minutes, and right now the U.S. death toll from strokes stands at upwards of 130,000 each year. Annually, more than 795,000 Americans suffer a stroke.

“Strokes will absolutely strain the healthcare system,” said Bruce Ovbiagele, M.D., M.Sc., professor and chairman of the Department of Neurology at the Medical University of South Carolina, Charleston. Caring for survivors is expensive because stroke can cause long-term disability, he said. “Ninety percent of stroke patients have residual disability and only 10 percent recover completely after a stroke,” Ovbiagele said. “Policy makers at all levels of governance should be aware of this looming crisis so that we can consider practical ways to avert it.”

Against the backdrop of these devastating statistics, CVR is poised to make a dramatic impact upon an industry starved for innovation and advancement.

The CSS is a groundbreaking tool that can assess Carotid Arterial health in a way that has never been available to a patient, healthcare provider, or the payor in our current healthcare system. Existing early detection systems cost anywhere between US$250,000 and US$2.5 million—and they aren’t economically feasible to use, so the indicators for a stroke go undetected and the concomitant medical bills continue to drown patients and government alike, while people suffering when it could be prevented.

From the 234,615 primary care offices, specialist offices and hospitals and clinics just in the U.S., the CSS has already identified a total U.S. market opportunity of $11.5 billion, assuming only one device is sold to each office. The global market, then, is gargantuan—and CVR expects to fully penetrate it.

2. The Dream Team Behind the Medical Miracle

The first thing that comes to mind when you meet the team behind CVR and the development of this breakthrough technology is an unheard-of modesty and professionalism. This team has demonstrated the strategic vision of a supergiant by leveraging intellectual property, market and industry know-how and key strategic relationships.

Led by Chairman, CEO and President Peter Bakema—with an impressive 30-year track record in business development, since its inception, CVR has brought on some of the most respected medical professionals in the industry.

  • Tony Robinson, COO and Executive Vice-President has been with CVR for 8 years and has extensive domestic and global healthcare experience.  
  • Michael Rhodes, VP of Quality Systems, is a former VP for Quality for HSBC and Motorola. He has 20 years of experience in multiple markets.
  • Dr. W. Douglas Weaver, a member of the BOD Scientific Advisory Board, is the former president of the American College of Cardiology and the former VP and System Medical Director of Heart and Vascular Services at Henry Ford Health System. His over 330 publications related to drug and device discovery have been some of the most influential in our time.

Together, they are on a trajectory which will revolutionize healthcare by offering easily accessible, affordable early detection for a potentially massive market share at a very critical time in our healthcare story.

3. Cashed Up, but Still Cheap and Ready to Burst through the Gates

CVR has already invested US$23 million into the research and development of their breakthrough CSS technology, and right now they’re at that critical juncture where investment turns into profit, so shares are still cheap—while they last, and that isn’t likely to be for long.

CVR is just coming out of early stage clinical trials, and is about to enter pivotal trials, which limits the window of opportunity between market and profitability. They’ve been in business for a decade, and now at the last stage before profitability.  

The critical timeframe to watch is the release of a preliminary clinical report in the near future followed by a full clinical report roughly 4-8 weeks later. Once that happens, the next step is FDA submission to prove safety and efficacy, and if successful, market clearance and delivery to the market.

Because the all-in costs are less than half the sale costs, the company is expecting a very quick and lucrative head start. The team has already lined up manufacturing and components, so once the clinical reports are in, and the FDA hurdle is cleared, it’s breakout time.

But it won’t stop here. This isn’t a one trick pony. CVR’s CSS is only the first in the application of the technology.

Soon enough, you could see these Carotid Stenotic Scan (CSS) in every doctor’s office, lab, hospital you visit...

With a potential market of some 235,000 medical offices, we’re looking at an immense market opportunity.

And this company is at the center of it all.

By. James Burgess of
Oilprice.com

Legal Disclaimer/Disclosure: This piece is an advertorial and has been paid for. This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. No information in this Report should be construed as individualized investment advice. A licensed financial advisor should be consulted prior to making any investment decision. We make no guarantee, representation or warranty and accept no responsibility or liability as to its accuracy or completeness. Expressions of opinion are those of Oilprice.com only and are subject to change without notice. Oilprice.com assumes no warranty, liability or guarantee for the current relevance, correctness or completeness of any information provided within this Report and will not be held liable for the consequence of reliance upon any opinion or statement contained herein or any omission. Furthermore, we assume no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of the use and existence of the information, provided within this Report.


             


© 2005-2017 http://www.MarketOracle.co.uk - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.


Post Comment

Only logged in users are allowed to post comments. Register/ Log in

Catching a Falling Financial Knife